In vitro antimicrobial activity of narasin and monensin in combination with adjuvants against pathogens associated with canine otitis externa.

(a-c) Minimal inhibitory concentration (MIC), fractional inhibitory concentration index (FICI) and dose reduction index (DRI) of the combination effect of (a) narasin and N-acetylcysteine (NAC), (b) narasin and Tris-EDTA and (c) narasin and disodium EDTA (a-c) Minimal inhibitory concentration (MIC), fractional inhibitory concentration index (FICI) and dose reduction index (DRI) of the combination effect of (a) monensin and N-acetylcysteine (NAC), (b) monensin and Tris-EDTA and (c) monensin and disodium EDTA for various bacterial isolates (a-c) Minimal inhibitory concentration (MIC), fractional inhibitory concentration index (FICI) and dose reduction index (DRI) of the combination effect of (a) monensin and N-acetylcysteine (NAC), (b) monensin and Tris-EDTA and (c) monensin and disodium EDTA for various bacterial isolates (a-c) Minimal inhibitory concentration (MIC), fractional inhibitory concentration index (FICI) and dose reduction index (DRI) of the combination effect of (a) monensin and N-acetylcysteine (NAC), (b) monensin and Tris-EDTA and (c) monensin and disodium EDTA for various bacterial isolates. [Extracted from the article]